Long-Term Safety of iPS Spinal Cord Therapy Confirmed in Japan
Researchers at Japan's Keio University have confirmed the long-term safety of iPS cell-derived neural progenitor cell transplants in patients with spinal cord injuries. No major safety issues or tumor formations were observed in patients two to four years post-surgery.
Why it matters
This milestone supports the viability of regenerative medicine using iPS cells, potentially opening doors for treating previously permanent neurological damage.
Tokyo, July 21 (Jiji Press)--Long-term safety has been confirmed after neural progenitor cells derived from induced pluripotent stem, or iPS, cells, were transplanted into patients with spinal cord injuries, a team of researchers at Japan's Keio University said Tuesday.
The team, which conducted the world's first clinical study of the treatment, plans to launch an investigator-initiated clinical trial as early as next year to bring it into practical use.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in